

SEARCH...

[HOME](#) [ABOUT US](#) [TECHNOLOGY](#) [PEOPLE](#) [NEWS & PUBLICATIONS](#) [LINKS](#)

## NEWS & PUBLICATIONS

[PRESS RELEASES](#)[PUBLICATIONS](#)

## PRESS RELEASES

A list of the most recent press releases issued by TREVENTIS Corporation are shown below. If you click on any listing, it will open to display the full text of the release. (Click again to close).

[JUNE 1, 2014 – Sean Cunliffe Joins TREVENTIS Corporation as CEO](#)

### **Sean Cunliffe Joins TREVENTIS Corporation as CEO**

#### ***Pharmaceutical/Biotechnology Veteran to Lead Dementia-Focused TREVENTIS Corporation***

June 1, 2014 – Philadelphia, PA and Toronto, Ontario – TREVENTIS Corporation announced today that Sean Cunliffe has joined the Company as its new CEO. With over 30-years' experience in both big pharma and biotechnology, including several other neurology-focused companies, Sean brings a wealth of experience to this position. L. William McIntosh, the retiring CEO, will remain active with the Company in an oversight role as he will continue as Chairman of the Board of Directors.

"We are delighted to have Sean join TREVENTIS as its new CEO. He has both the experience and successful track record that is needed to assure the Company's success as it pursues new financing and potential partnerships for its important discoveries" said William McIntosh, Chairman.

Sean started his career in the industry with Astra Canada in the early 1980's. At Glaxo Wellcome Canada and the US for over a decade, Sean launched many major medicines and was promoted through increasingly senior management positions including the US-based Director, Global Marketing for CNS diseases and Group Director GI and anti-virals. Sean joined Wyeth Pharmaceuticals in Collegeville PA in 2001 and during his tenure, served as Vice President of Marketing for three therapeutic groups, including co-chairing the therapeutic area leadership teams for CNS and Cardiovascular/Metabolic diseases. In 2005, Sean joined Neuromed Pharmaceuticals (now Zalicus) becoming Chief Commercial Officer. There, over four years, Sean led three major licensing deals and participated in several rounds of venture financing, raising a total of \$190 million and propelling Neuromed from a Phase I company to a commercial-ready organization with an FDA approved NDA. From 2009 to 2011, Sean served as Senior Vice President of Angiotech Pharmaceuticals, a public medical device company with over 1,600 global employees. Since late 2011, Sean served as the consulting CBO for Sirona Biochem and is the CEO for Sitka Biosciences both of Vancouver, B.C.

#### **About TREVENTIS Corporation**

TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Toronto, Ontario, and Halifax, Nova Scotia, Canada. The company is focused on the discovery and early stage development of disease-modifying small molecule drugs for Alzheimer's and other protein misfolding diseases. In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring of treatment effects in Alzheimer's disease. [www.TREVENTIS.com](http://www.TREVENTIS.com)